2CUREX AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4 SEK | +6.38% |
|
+32.45% | -80.10% |
| Feb. 29 | 2curex AB Elects Grith Hagel as a New Board Member | CI |
| Feb. 22 | 2cureX AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 7.39M 697K | Sales 2022 | 3.37M 318K | Capitalization | 143M 13.54M |
|---|---|---|---|---|---|
| Net income 2021 | -18M -1.7M | Net income 2022 | -29M -2.74M | EV / Sales 2021 | 29.9 x |
| Net cash position 2021 | 72.94M 6.88M | Net cash position 2022 | 44.89M 4.24M | EV / Sales 2022 | 29.3 x |
| P/E ratio 2021 |
-14.6
x | P/E ratio 2022 |
-4.81
x | Employees | 14 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 34.45% |
More Fundamentals
* Assessed data
More news
Latest transcript on 2cureX AB
More press releases
| 1 day | +6.38% | ||
| 1 week | +32.45% | ||
| Current month | -12.28% | ||
| 1 month | +9.89% | ||
| 3 months | -74.76% | ||
| 6 months | -81.82% | ||
| Current year | -80.10% |
1 week
0.27
0.43
1 month
0.200.60
Current year
0.202.79
1 year
0.205.98
3 years
0.2020.45
5 years
0.2031.50
10 years
0.2031.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 21-01-31 | |
Grith Hagel
FOU | Founder | 65 | 05-12-31 |
Ole Thastrup
FOU | Founder | 71 | 05-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ole Thastrup
FOU | Founder | 71 | 05-12-31 |
| Chairman | - | Nov. 13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-29 | 0.4 | +6.38% | 4 900 |
| 24-05-28 | 0.376 | -6.00% | 3,514 |
| 24-05-27 | 0.4 | +28.21% | 119,202 |
| 24-05-24 | 0.312 | -9.57% | 20,908 |
| 24-05-23 | 0.345 | +14.24% | 93,982 |
Delayed Quote Nasdaq Stockholm, May 29, 2024 at 03:00 am EDT
More quotes
2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.
Calendar
2024-05-29
- Q1 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -80.10% | 628K | |
| -36.44% | 8.68B | |
| -3.29% | 3.2B | |
| +19.31% | 2.71B | |
| -18.71% | 2.04B | |
| -22.03% | 1.64B | |
| +64.58% | 1.43B | |
| +34.58% | 841M | |
| -7.42% | 718M | |
| -25.51% | 538M |
- Stock Market
- Equities
- 2CUREX Stock
